Clinical trial · Interventional
Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization
Prospective Blinded Study Looking at PO/IV Analgesia Alone Versus PO/IV Analgesia With Superior Hypogastric Nerve Block for Uterine Artery Embolization Pain Management
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Uterine fibroid embolization (UFE) is now an accepted treatment of uterine fibroids. However the procedure is often very painful and, in many centres, patients are admitted overnight with patient controlled analgesic (PCA) pumps for pain control and discharged the next day with heavy pain medications. The goal of this study is to evaluate the effectiveness of a superior hypogastric nerve block (SHGNB) in controlling the pain post-UFE.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leiomyoma | Leiomyoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 0.75% Ropivacaine | Drug | — | UNRESOLVED |
| 1% Xylocaine | Drug | — | UNRESOLVED |
| Subcutaneous injection | Procedure | — | UNRESOLVED |
| Superior hypogastric nerve block | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- SHAM_COMPARATOR
- label
- Control group
- description
- Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
- interventionNames
- Procedure: Subcutaneous injection
- Drug: 1% Xylocaine
- type
- EXPERIMENTAL
- label
- Sup Hypogastric Nerve block group
- description
- Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.
- interventionNames
- Procedure: Superior hypogastric nerve block
- Drug: 0.75% Ropivacaine
Primary outcomes (1)
- measure
- mg Equivalent Morphine Used Until Discharge From Recovery Room to Control Pain Level Below 4/10 (VAS)
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: 1. All women with symptomatic fibroids or adenomyosis that have requested and been approved for uterine artery embolization 2. Ability to comply with the requirements of the study procedures Exclusion Criteria: 1. Patients in whom the vascular anatomy prevents access to the superior hypogastric nerve plexus safely 2. Patients who have known allergy to the anesthetic agent 3. Patients with signs of skin infection at the entry site of the needle used to place the nerve block 4. Patients with signs of infection such as fever 5. Patients with history of inflammatory bowel disease of with signs of colitis 6. Patients with uncorrectable abnormal coagulation status (INR \>1.5 and plt \< 50000 without use of anticoagulation agents) 7. Patients with preexisting conditions, which, in the opinion of the investigator, interfere with the conduct of the study. 8. Patients who are uncooperative, cannot follow instructions, or who are unlikely to comply with follow-up appointments or fill-out the post-procedural pain questionnaires. 9. Patients with a mental state that may preclude completion of the study procedure or is unable to provide informed consent
References
Publications (2)
- BACKGROUNDRasuli P, Jolly EE, Hammond I, French GJ, Preston R, Goulet S, Hamilton L, Tabib M. Superior hypogastric nerve block for pain control in outpatient uterine artery embolization. J Vasc Interv Radiol. 2004 Dec;15(12):1423-9. doi: 10.1097/01.RVI.0000137406.09852.A4. PMID 15590800
- DERIVEDYoon J, Valenti D, Muchantef K, Cabrera T, Toonsi F, Torres C, Bessissow A, Bandegi P, Boucher LM. Superior Hypogastric Nerve Block as Post-Uterine Artery Embolization Analgesia: A Randomized and Double-Blind Clinical Trial. Radiology. 2018 Oct;289(1):248-254. doi: 10.1148/radiol.2018172714. Epub 2018 Jul 10. PMID 29989515